Clinical Trial Search

Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04

Primary: Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) — -14.354; -12.648; -13.742; -13.927 %…

Primary: Quality of Life Scale in Alzheimer's Disease (QOL-AD) — 38.8; 40.0 score on a scale — p=0.14

Primary: Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort — 6.9…

Primary: Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — 88.3; 88.1; -15.3; -13.4 score on a scale — p=0.0940

Primary: Change From Baseline to Week 12 in Mean Pain Intensity — 0.6; 1.7 score on a scale

Primary: Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery — 111; 102 participants — p=0.84

Primary: Rate of Serious Bacterial Infection (SBI) Per Participant Per Year — 0; 0.023; 0.017 Rate of events per participant per year

Primary: Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and Strata — 86.1; 29.4 Percentage of participants — p=<.001

Primary: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment — -21.6; -17.6; -17.8 units on a scale…

Primary: Chest Tube Drainage — 200; 225; 375; 400 mL

Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 995; 351…

Primary: Incidence of Adverse Events — 530.8; 514.2 Events per 100 patient years

Primary: Change in Hemoglobin A1c (HbA1c) From Baseline — -1.53; -1.71; -1.87 Percentage of HbA1c — p=0.003

Primary: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks — 68; 66 Participants — p=0.99